Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
about
Antioxidants and other pharmacological treatments for Friedreich ataxiaAntioxidants and other pharmacological treatments for Friedreich ataxiaTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesIron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxiaFerritin for the clinicianMolecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesisSplice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intoleranceEfficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromesWorld health dilemmas: Orphan and rare diseases, orphan drugs and orphan patientsTherapeutic developments in Friedreich ataxiaIron chelation and multiple sclerosisMitochondria as a therapeutic target in heart failureMitochondrial iron-sulfur cluster dysfunction in neurodegenerative diseaseIron homeostasis and toxicity in retinal degenerationGenetics of neurodegeneration with brain iron accumulationIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesPharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxiaCerebellar pathology in Friedreich's ataxia: atrophied dentate nuclei with normal iron content.Common data elements for clinical research in Friedreich's ataxia.The role of iron in brain ageing and neurodegenerative disorders.Effect of Water T2 Shortening in the Quantification of in-vitro Proton MR Spectroscopy.Overview of quantitative susceptibility mapping.Deferiprone targets aconitase: implication for Friedreich's ataxia treatmentLimitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screenFlavin adenine dinucleotide rescues the phenotype of frataxin deficiency.Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation.Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Past, present and future therapeutics for cerebellar ataxias.Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.Intracellular iron transport and storage: from molecular mechanisms to health implications.Advances in iron chelation: an update.Design of iron chelators with therapeutic application.Inherited cerebellar ataxia in childhood: a pattern-recognition approach using brain MRI.The oral iron chelator deferiprone protects against iron overload-induced retinal degenerationIdentification of mineral deposits in the brain on radiological images: a systematic review.Normal and Friedreich ataxia cells express different isoforms of frataxin with complementary roles in iron-sulfur cluster assemblyLoss of Frataxin induces iron toxicity, sphingolipid synthesis, and Pdk1/Mef2 activation, leading to neurodegeneration.Pharmacological treatments for Friedreich ataxia.
P2860
Q24200235-CB5344AA-80E6-48EA-BC4A-BF233BF0AC41Q24240370-E5D4461B-026F-4267-820B-C6252D53BE71Q24289511-26FC6E0C-430E-4A23-B45D-308436B9E077Q24323371-E04ED6E6-FB75-472D-BD05-6EEEBA556801Q24642942-DEACD160-8F40-4F02-AB74-181D0974E755Q24646911-689E9B8D-5A48-4262-9336-7FEA124FF0A8Q24656037-232962FC-1CF7-4582-98E2-4F8934A21727Q26764818-CC14C0E9-A003-4B55-B729-DD887BFA6579Q26826936-5622B4C9-E963-4B96-9B9E-F844AB832AAFQ26861733-48F8BD36-79B8-45A0-8DC1-7B2066130CD8Q27001743-B12C5241-4608-4A9C-820C-CF65E37C70C7Q27005632-BBF19D4C-C952-4B1A-A140-30EB3C0F1D4AQ27015737-CBBE0369-BF38-45FB-9B55-546BD31DD5AAQ28252419-48C71F32-64F7-4A3F-84A6-5BD1DA6DA8C1Q28304487-E4E0E793-ABFC-455F-8446-47BC7AD28798Q28388335-ABE53425-D56C-4421-8339-511D5C00CDB5Q28486160-49DB5C02-1B98-4ED5-B768-FE26605556F9Q30426640-2411146E-300B-41D3-A376-6398C3A466CEQ30581588-CC6E0F22-87AD-47B0-B54C-B6FB73BB46E8Q30852753-31E58546-D471-4330-B0CD-ED73B19D4A7AQ30956055-0D2494F7-2C41-40E3-BF10-D631CDA707C6Q31115799-20A51720-C0B8-41B5-8D4C-79D572FC8A4FQ33344109-1A724035-2962-4F17-A02F-920B6E37A9FEQ33496330-1EC7B19E-CD86-47EC-9579-971845BD102DQ33527398-8AD986A8-3AAB-4812-B94E-D4346B6C7994Q33555894-A37A2D59-C495-4830-8B8E-0BE1F45D91C7Q33684033-EC08614D-4FDD-4E17-A65B-C9D587E08745Q33701891-BF9A14B1-8247-4D4E-9823-26B8151FEBDEQ33768106-9CDFA482-3695-4B1D-ABE2-E94101BB284BQ33836935-02E0A131-3118-4761-AE78-B744B15E16C3Q34076650-9E3442C5-F8F6-4F34-A4FC-069E16A7D04CQ34100135-D002C7F8-47CF-46C9-A28F-4BCEF0F3E2A3Q34174307-8AF902EA-EEF6-438E-AD1A-FAB13D856F2AQ34258805-63F7B4A2-EE62-4259-BFF0-E494D9BF3656Q34272973-F66C670F-FC0A-476E-9AD2-CCE017993B75Q34281402-83B7525B-0E10-4933-BA16-3841FE93D50BQ34300363-CB02F6BB-4C4E-4AAA-9C5B-F98AEBF5C299Q34352285-801C6413-F6E6-4464-BED2-5F977B6A576CQ34531992-7F45B5F3-1B7A-4767-B5F7-E6B5ECFDE80FQ34538823-B5E04A3C-25AF-4C5B-8291-2F2BE2385AD6
P2860
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
@en
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
@nl
type
label
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
@en
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
@nl
prefLabel
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
@en
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
@nl
P2093
P1433
P1476
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
@en
P2093
Anne Leroy-Willig
Daniel Sidi
Francis Brunelle
Jean-Christophe Thalabard
Kim Hanh Le Quan Sang
Nathalie Boddaert
Serge Gallet
Z Ioav Cabantchik
P304
P356
10.1182/BLOOD-2006-12-065433
P407
P577
2007-03-22T00:00:00Z